Stifel Reiterates Buy Rating on Rapport Therapeutics (RAPP) following Q4 report
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $56.00 price target on Rapport Therapeutics (NASDAQ: RAPP)The analyst commented, "We're ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
